abs250.txt	mutations	in	tumor	suppressor	tp53	have	been	inconsistently	linked	to	breastcancer	risk	factors	and	survival		immunohistochemistry	(ihc)	staining		a	primaryclinical	means	of	tp53	mutation	determination		only	detects	mutations	thatfacilitate	protein	accumulation	(e	g			missense	mutations)		rna-based	pathwaymethods	capture	functional	status	and	may	aid	in	understanding	the	role	of	tp53function	in	racial	disparities	of	breast	cancer		tp53	status	was	assessed	amonginvasive	breast	cancer	cases	from	the	carolina	breast	cancer	study	(cbcs)(2008-2013)	using	ihc	and	an	established	rna-based	tp53	signature	(cbcs	and	thecancer	genome	atlas	(tcga))		frequency	of	tp53	status	(ihc		rna-based)	wasestimated	in	association	with	tumor	characteristics		pam50	intrinsic	subtype	age		and	race	using	relative	frequency	differences	(rfds)	and	95%	confidenceintervals	(95%	ci)	as	the	measure	of	association		approximately	60%	of	basal-liketumors	were	tp53	protein	positive	(ihc)		while	nearly	100%	were	tp53	mutant-like(rna)		luminal	a	tumors	had	low	frequency	of	tp53	positivity	(ihc		7	9%)	andmutant-like	status	(rna		1	7%)		mutant-like	tp53	(rna)	was	strongly	associatedwith	age	â‰¤50	years		high	tumor	grade		advanced	stage	of	disease		large	tumorsize		and	basal-like	and	her2	intrinsic	subtypes		black	race	was	stronglyassociated	with	tp53	mutant-like	status	(rna)	(rfd		24	8%		95%	ci		20	5		29	0)even	after	adjusting	for	age		grade		stage	(rfd		11	3%		95%	ci		7	6		15	0)	associations	were	attenuated	and	non-significant	when	measured	by	ihc		ihc-basedtp53	status	is	an	insensitive	measurement	of	tp53	functional	status		rna-basedmethods	suggest	a	role	for	tp53	in	tumor	prognostic	features	and	racialdisparities	
